In vitro activity of synthetic antimicrobial peptides against Candida

• Autorzy: Kamysz W , Nadolski P. , Kedzia A. , Cirioni O. , Barchiesi F. , Giacometti A. , Scalise G. , Lukasiak J. , Okroj M.
• Języki publikacji: EN

Abstrakty

EN

Yeast-like fungi are the most common cause of fungal infections in humans. Actually, in the age of opportunistic infections and increasing resistance, development of modern antifungal agents becomes a very important challenge. This paper describes synthesis and antimicrobial assay of four naturally occurring peptide antibiotics (aurein 1.2, citropin 1.1, temporin A, uperin 3.6) and three chemically engineered analogues actually passing clinical trials (iseganan, pexiganan, omiganan) against Candida strains isolated from patients with infections of the oral cavity or respiratory tract. The peptides were synthesized using solid-phase method and purified by high-performance liquid chromatography. Biological tests were performed using the broth microdilution method. The antifungal activity of the peptide antibiotics was compared to that of nystatin and amphotericin B. We found synthetic peptides to be generally less potent than amphotericin B or nystatin. However, some of the naturally occurring peptides still retained reasonable antifungal activities which were higher than these of iseganan, pexiganan or omiganan. We think that the naturally occurring peptide antibiotics included in our study can be a good matrix for development of novel antifungal compounds.

Słowa kluczowe

EN

yeast-like fungi; activity; man; peptide; antimicrobial peptide; Candida; fungi; antimicrobial activity; in vitro; synthetic antimicrobial peptide; fungal infection

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2006
• Tom: 55
• Numer: 4
• Opis fizyczny: p.303-307,ref.

Twórcy

autor

Kamysz W

• Medical University of Gdansk, Al.Gen.Hallera 107, 80-416 Gdansk, Poland

autor

Nadolski P.

autor

Kedzia A.

autor

Cirioni O.

autor

Barchiesi F.

autor

Giacometti A.

autor

Scalise G.

autor

Lukasiak J.

autor

Okroj M.

Bibliografia

• Barchiesi R, L.R Di Francesco, R Compagnucci, D. Arzeni, A. Giacometti and G. Scalise. 1998. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J. Antimicrob. Chemother. 41: 59-65.
• Branchini M.L., F.H. Aoki, A.L. Colombo, H. Taguchi, K. Yamamoto and M. Miyazi. 1998. Effect of antifungal agents on Candida spp. and Pichia anomala isolated from oropharyngeal candidiasis of AIDS patients in a University Hospital in Brazil. Braz. J. Infect. Dis. 2: 187-196.
• Chen J., T.J. Falla, H. Liu, M.A. Hurst, C.A. Fujii, D.A. Mosea, J.R. Embree, D.J. Loury, P.A. Radel, C. Cheng Chang, L. Gu and J.C. Fiddes. 2000. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers 55: 88-98.
• Chia B.C., J.A. Carver, T.D. Mulhern and J.H. Bowie. 1999. The solution structure of uperin 3.6, an antibiotic peptide from the granular dorsal glands of the Australian toadlet, Uperoleia mjobergii. J. Pept. Res. 54: 137-145.
• Christensen T. 1979. Qualitative test for monitoring coupling completeness in solid phase peptide synthesis using chloranil. Acta Chem. Scand. Series B. (Org. Chem. Biochem.) 33: 763-776.
• CLSI. 2002. Antifungal susceptibility testing of yeasts. Approved standard-second edition. Document M-27A2. Clinical and Laboratory Standards Institute, Wayne, Pa.
• Conlon J.M., J. Kolodziejek and N. Nowotny. 2004. Antimicrobial peptides'from ranid frogs: taxonomic and phylo-genetic markers and a potential source of new therapeutic agents. Biochim. Biophys. Acta 1696: 1-14.
• de Paiva Martins C.A., C.Y. Koga-Ito and A.O.C. Jorge. 2002. Presence of Staphylococcus spp. and Candida spp. in the human oral cavity. Braz. J. Microbiol. 33: 236-240.
• Fields G.B. and R.L. Noble. 1990. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35: 161-214.
• Georgopapadakou N.H. 1998. Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. 1: 547-557.
• Kamysz W. 2005. Are antimicrobial peptides an alternative for conventional antibiotics? Nucl. Med. Rev. Cent. East Eur. 8: 78-86.
• Karabinis A., C. Hill, B. Leclercq, C. Tancrede, D. Baume and A. Andremont. 1988. Risk factors for candidemia in cancer patients: a case-control study. J. Clin. Microbiol. 26: 429-432.
• Law D., C.B. Moore, H.M. Wardle, L.A. Ganguli, M.G. Keaney and D.W. Denning. 1994. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J. Antimicrob. Chemother. 34: 659-68.
• Marchetti O., P. Moreillon, J.M. Entenza Vouillamoz, M.P Glauser, J. Bille and D. Sanglard. 2003. Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDRl, and FLU1 genes. Antimicrob. Agents Chemother. 47: 1565-1570.
• Nierebińska E., Z. Gwieździński, S. Urbanowski and M. Pracz. 1992. Phenomenon of increased resistance of yeast-like fungi to nystatin. Wiad. Lek. (in Polish) 45: 427-429.
• Prasad R., S.L. Panwar and M. Smriti. 2002. Drug resistance in yeasts an emerging scenario. Adv. Microb. Physiol. 46: 155-201.
• Punzon C, S. Resino, J.M. Bellon, M.A. Munoz-Fernandez and M. Fresno. 2002. Analysis of the systemic immune response in HIV-1 -infected patients suffering from opportunistic Candida infection. Eur. Cytokine Netw. 13: 215-223.
• Rozek T., K.L. Wegener, J.H. Bowie, I.N. Olver, J.A. Carver, J.C. Wallace and M.J. Tyler. 2000. The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2. Eur. J. Biochem. 267: 5330-5341.
• Vanden Bossche H., F. Dromer, I. Improvisi, M. Lozano-Chiu, J.H. Rex and D. Sanglard. 1998. Antifungal drug resistance in pathogenic fungi. Med. Mycol. 36: 119-128.
• Vazquez J.A. 2003. Treatment of candidiasis in hospitalized patients. Curr. Treatm. Options Infect. Dis. 5: 495-506.
• Wegener K.L., P.A. Wabnitz, J.A. Carver, J.H. Bowie, B.C. Chia, J.C. Wallace and M.J. Tyler. 1999. Host defence peptides from the skin glands of the Australian blue mountains tree-frog Litoria citropa. Solution structure of the antibacterial peptide citropin 1.1. Eur. J. Biochem. 265: 627-637.
• Wong-Beringera A., J. Hindler, L. Brankovic, L. Muehlbauer and L. Steele-Moore. 2001. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients. Diagn. Microbiol. Infect. Dis. 9: 025-31.
• Zuber T.J. and K. Baddam. 2001. Superficial fungal infection of the skin. Where and how it appears help determine therapy. Postgrad. Med. 109: 117-120, 123-126, 131-132.